جستجوی استاد راهنمای دانشگاهی

Kimberley Evasonمشاهده پروفایل

دانشیار

• Liver Cancer
• Hepatocellular Carcinoma (HCC)
• Wnt/β-catenin Signaling
• +۳ مورد دیگر

Kimberley Evason serves as Associate Professor of Anatomic Pathology in the Department of Pathology at the University of Utah School of Medicine and Adjunct Assistant Professor of Oncological Sciences. Her research program at the Huntsman Cancer Institute focuses on liver cancer mechanisms and therapeutic development, leveraging zebrafish models to address critical challenges in hepatocellular carcinoma treatment. Education: B.S. from University of Iowa M.D. and Ph.D. from Washington University School of Medicine Dr. Evason's laboratory investigates β-catenin-activated hepatocellular carcinoma (HCC), which accounts for 20-40% of human cases. Her team developed transgenic zebrafish models expressing hepatocyte-specific activated β-catenin that develop HCC, enabling chemical screening for targeted therapies. Key discoveries include JNK inhibitors and serotonergic antidepressants (notably amitriptyline) that suppress tumor growth, with amitriptyline showing efficacy in mouse models. Current research explores molecular mechanisms of drug action and identifies conserved genetic pathways through RNA-seq analysis and functional validation in zebrafish and human cell lines. Analysis of her 2015-2019 publications reveals a cohesive research trajectory centered on liver cancer biology using zebrafish models. Her work integrates chemical screening, genetic analysis, and translational validation across multiple systems (zebrafish, mouse, human cells), with strong emphasis on Wnt/β-catenin signaling pathways. Publications span molecular mechanisms, tumor microenvironment interactions, and diagnostic innovations, demonstrating consistent focus on bridging basic science discoveries to clinical applications in HCC treatment. Dr. Evason leads a multidisciplinary research team at the Huntsman Cancer Institute, utilizing core facilities for zebrafish husbandry and advanced imaging. Her collaborative network includes oncologists, geneticists, and pharmacologists across the University of Utah, facilitating translational research from bench to bedside. The laboratory's resources and institutional support enable high-throughput chemical screening and sophisticated molecular analyses central to her therapeutic discovery pipeline.

Lisa Lesniewskiمشاهده پروفایل

دانشیار

• Aging
• Obesity
• Adipose Tissue Biology
• +۸ مورد دیگر

Lisa Lesniewski, Ph.D. , is an Associate Professor of Internal Medicine at the University of Utah School of Medicine and an Adjunct Assistant Professor of Nutrition and Integrative Physiology. She directs an active research program investigating the vascular and metabolic consequences of aging and obesity, with emphasis on adipose tissue biology, arterial dysfunction, and atherosclerosis. Education B.S., Ohio State University Ph.D., Texas A&M University Research Interests Dr. Lesniewski’s laboratory explores how aging and obesity synergistically impair vascular and metabolic health. Central themes include: Adipose tissue as an endocrine organ driving systemic inflammation and metabolic dysfunction. Telomere dysfunction and cellular senescence in adipose and arterial tissues. mTOR signaling and the potential of rapamycin-based interventions to counter vascular aging. MicroRNA networks—especially miR-92a—in arterial growth, aging, and atherosclerosis. The small GTPase ARF6 as a mechanosensitive regulator of endothelial inflammation and atherogenesis. Research Output & Trends Across more than 40 peer-reviewed publications (2019-2024), her group has advanced a translational pipeline from molecular mechanism (DNA damage, telomere uncapping, senolytic therapy) to organismal phenotype (arterial stiffness, glucose intolerance, atheroma burden) in both mouse models and human cohorts. A consistent innovation is the integration of high-resolution imaging biosensors with in-vivo vascular phenotyping to dissect single-cell metabolic heterogeneity within aged and obese tissues. Scientific Awards & Honors No specific awards are listed in the provided materials. Funding & Collaborative Networks Dr. Lesniewski has sustained NIH funding for projects spanning vascular aging, adipose inflammation, and metabolic dysfunction. She actively collaborates with investigators in Molecular Biology, Nutrition and Integrative Physiology, and Cardiovascular Medicine at the University of Utah, as well as with national geroscience consortia. Laboratory & Teams The Lesniewski Laboratory is housed within the University of Utah’s Molecular Medicine Program and has access to core facilities in metabolic phenotyping, advanced microscopy, and small-animal cardiovascular physiology. The team comprises post-doctoral fellows, graduate students, and research technicians working on parallel but integrated projects aimed at translating pre-clinical discoveries into therapeutic strategies for age-related cardiometabolic disease.

Anna Zolkiewskaمشاهده پروفایل

استاد

• Triple negative breast cancer
• Tumor immune microenvironment
• ADAM metalloproteases
• +۴ مورد دیگر

Dr. Anna Zolkiewska is a Professor in the Department of Biochemistry & Molecular Biophysics at Kansas State University where she serves as an Undergraduate Advisor. Her research program focuses on understanding the molecular mechanisms underlying triple-negative breast cancer (TNBC), with particular emphasis on tumor-initiating cells and the tumor microenvironment. She maintains active research collaborations through the Johnson Cancer Research Center and has been featured in their Conquest magazine publications in both 2012 and 2021. Education: M.S. (1984), University of Warsaw, Poland Ph.D. (1988), Nencki Institute of Experimental Biology, Warsaw, Poland Dr. Zolkiewska's research centers on the molecular mechanisms responsible for immunosuppression in triple-negative breast cancer. Her laboratory investigates how cell surface metalloproteases from the ADAM family, particularly ADAM12, contribute to the assembly of the immunosuppressive tumor microenvironment in TNBC. She employs multi-disciplinary approaches spanning biochemistry, molecular and cellular biology, and mouse models of human TNBC to discover mechanisms controlling immune cell infiltration into breast tumors. A significant portion of her work focuses on breast tumor-initiating cells (BTICs), which are resistant to conventional chemotherapy and radiotherapy and are believed to drive tumor recurrence and metastasis. Analysis of Dr. Zolkiewska's recent publications reveals a consistent focus on ADAM proteases, particularly ADAM12, and their role in breast cancer progression. Her work demonstrates how these metalloproteases influence cancer stem cell phenotypes, immune evasion mechanisms, and response to immunotherapies. A notable trend in her recent work is the exploration of ADAM12's role in modulating the tumor immune microenvironment and improving response to checkpoint blockade therapy, representing a shift toward more translational cancer immunology research. Scientific Recognition: Featured in Johnson Cancer Research Center's Conquest magazine (2012) Featured in Johnson Cancer Research Center's Conquest magazine (2021) As an active researcher and educator, Dr. Zolkiewska serves as an Undergraduate Advisor while maintaining a productive research program. Her laboratory has received research funding through various mechanisms including the Johnson Cancer Research Center's Innovative Research Awards and other cancer research funding opportunities at Kansas State University. Dr. Zolkiewska's work bridges basic molecular mechanisms with potential clinical applications, particularly in improving immunotherapy responses for triple-negative breast cancer patients. Her research team employs sophisticated biochemical, molecular, and cellular approaches to investigate cancer mechanisms, with recent work increasingly incorporating immunological perspectives and mouse models of human disease. This multi-faceted approach allows her laboratory to address complex questions about tumor biology from multiple angles.

Thuy Anh Buiمشاهده پروفایل

پژوهشگر ارشد

• Clinical Rehabilitation
• Musculoskeletal Diseases
• Health Service Research
• +۴ مورد دیگر

Thuy Anh Bui is a Senior Research Fellow at the University of New South Wales, Faculty of Medicine, specializing in clinical rehabilitation and translational research. Originally from Vietnam, she completed her BSc and PhD in Physiology at the University of Manchester before transitioning from laboratory-based cardiovascular and cancer gene therapy research into clinical applications. Her current work bridges laboratory innovation with practical healthcare solutions, particularly for hip fracture patients in culturally diverse communities. Her research interests focus on clinical rehabilitation , musculoskeletal diseases , and health service research for culturally and linguistically diverse populations. She has published in high-impact journals including Nature Communications, Lancet eBiomedicine, and Advanced Functional Materials, demonstrating expertise that spans from basic science to clinical implementation. Her recent work shows a clear trajectory from cardiovascular and cancer gene therapy toward rehabilitation research, particularly in home-based care models. Bui leads the 'Rehabilitation in the Home' (RITH4Hips) randomized controlled trial, which received a $493,233 HCF Health Services Research Grant. This work builds on her previous success as project manager for the Hospital in the Home for Hip Fracture project at Liverpool Hospital, which was named a 2025 SWSLHD Quality Awards Finalist for Health Research. SWSLHD Quality Awards Finalists in Health Research, 2025 President's Doctoral Scholar Award, University of Manchester, UK, 2014-2018 Award for Excellence, Faculty of Life Sciences, University of Manchester, UK 2014 Outstanding Achievement Award, Faculty of Life Sciences, University of Manchester, UK, 2012 Silver Medal - 21st International Biology Olympiad 2010 First Prize - National Biology Olympiad, Vietnam 2010 As a supervisor, Bui is available to mentor ILP, Honours, Master, and PhD students in clinical trials for rehabilitation and musculoskeletal health, health service research for diverse populations, and translational research. Her community engagement work focuses on South West Sydney's culturally diverse communities, ensuring research addresses real-world healthcare disparities. She holds a Graduate Certificate in Higher Education Teaching and Learning from University of Technology Sydney, enhancing her capacity to develop future researchers.

• Pulmonary Fibrosis
• Influenza Virus Research
• MicroRNA Biology
• +۵ مورد دیگر

Chaoqun Huang serves as a Research Assistant Professor in the Department of Physiological Sciences at Oklahoma State University, where they have been employed since 2018. Their research primarily focuses on molecular mechanisms underlying pulmonary diseases and viral infections, with particular emphasis on non-coding RNA regulation. Huang's research interests span several interconnected areas including pulmonary fibrosis pathogenesis, influenza virus and SARS-CoV-2 infection mechanisms, and the regulatory roles of microRNAs and long non-coding RNAs. Their work has significantly contributed to understanding how non-coding RNAs modulate viral replication and lung fibrosis processes. Notable research includes investigations into FENDRR, miR-9-1, miR-206, and other regulatory RNAs in the context of respiratory diseases. Analysis of their recent publications reveals a strong focus on identifying novel antiviral and anti-fibrotic mechanisms involving non-coding RNAs. Their work demonstrates how these molecules can serve as potential therapeutic targets for conditions like idiopathic pulmonary fibrosis and influenza virus infection. Huang frequently employs molecular biology techniques, animal models, and advanced sequencing approaches to uncover fundamental mechanisms of disease pathogenesis. Huang has received recognition for their contributions to understanding the molecular basis of pulmonary diseases and viral infections, as evidenced by citations across multiple publications. Their research has implications for developing novel therapeutic strategies targeting non-coding RNA pathways in respiratory diseases. Through collaborative research efforts, Huang has established expertise in both pulmonary fibrosis and viral pathogenesis, creating a unique interdisciplinary approach that bridges these two important areas of respiratory medicine. Their work continues to explore the complex interplay between host factors and disease mechanisms in the lung.

• Molecular Genetics
• Epigenetics
• Paediatric Neuro-oncology
• +۴ مورد دیگر

Tania Corbett-Jones serves as a Research Fellow at the Centre for Genomics and Child Health within the Blizard Institute, Faculty of Medicine and Dentistry at Queen Mary University of London. She has been affiliated with Queen Mary since 2006, conducting collaborative research in bioinformatic pathway analysis, network modeling of experimental data, and karyotypic studies of human cell lines and primary tumors. Her research specializes in molecular mechanisms driving pediatric low-grade gliomas (pLGG), with particular focus on comparing pilocytic astrocytomas harboring KIAA1549-BRAF fusions versus glioneuronal tumors with BRAF V600E mutations. Both aberrations activate MAPK signaling but produce distinct phenotypes. She employs integrated multi-omics approaches combining RNA sequencing, LncRNA arrays, and phospho-proteomic analysis with Kinase-Substrate Enrichment Analysis (KSEA) to dissect downstream signaling mechanisms. This work aims to identify critical molecular effectors and validate findings using isogenic models developed in her laboratory. Publication trends reveal consistent progression from genetic characterization (2009-2011) toward sophisticated multi-omics integration (2015-2020), with increasing emphasis on epigenetic regulation and pathway crosstalk in pLGG. Her work spans molecular oncology, neurogenetics, and computational biology, primarily published in specialized journals like Acta Neuropathologica Communications and EMBO Reports. Within the Centre for Genomics and Child Health, Dr. Corbett-Jones collaborates across research groups utilizing core genomic and proteomic facilities. Her laboratory actively develops isogenic models to functionally validate molecular findings in pediatric glioma pathogenesis, contributing to translational research pipelines targeting MAPK pathway dysregulation.

• Medical Oncology
• Pathology
• Cancer Prognostic Biomarkers
• +۴ مورد دیگر

Thomas Karsten Kilvær is an Associate Professor at the Department of Clinical Medicine , UiT The Arctic University of Norway. He is a member of the Translational Cancer Research Group (TCRG) and contributes to the AI–Pathology project. Research Focus : Prognostic biomarkers in cancer pathology, tumor microenvironment dynamics, and machine learning applications in histological analysis. Key Collaborations : Regular co-authorship with researchers like Mehrdad Rakaee, Sigve Andersen, and Roy M. Bremnes. Scientific Publications (selected) highlight trends in NSCLC , colon cancer , and soft tissue sarcomas , emphasizing immune cell infiltration, microRNA expression, and computational pathology. Current Projects include digital outpatient services for health literacy and AI integration in cancer diagnostics.

Gwenn A. Gardenمشاهده پروفایل

استاد

• Alzheimer's Disease
• Neuroinflammation
• Neurodegeneration
• +۷ مورد دیگر

Gwenn A. Garden, MD, PhD is a Professor of Neurology and Chair of the Department of Neurology at the UNC School of Medicine . She also serves as Co-Director of the Duke/UNC Alzheimer's Disease Research Center , focusing on translational research in neurodegenerative diseases. Alzheimer's disease pathogenesis Neuroinflammation regulation Molecular cascades in neuronal degeneration Human tissue/stem cell research integration Her research bridges basic science with clinical applications, emphasizing neuroimmunology and microglial biology . Recent publications highlight her work on: 2023: Microglial transcriptomic changes in AD 2020: Cytokine roles in CAR T-cell neurotoxicity 2016: MicroRNA regulation of CNS inflammation Certifications and training: American Board of Psychiatry and Neurology (2012) MD and PhD in Physiology/Biophysics (University of Washington) Residency in Neurology (Harvard Longwood Program)

David Humphreysمشاهده پروفایل

پژوهشگر

• Bioinformatics
• Transcriptomics
• MicroRNAs
• +۶ مورد دیگر

David Humphreys is a Senior Scientist and bioinformatician at the Victor Chang Cardiac Research Institute, affiliated with the University of New South Wales. He manages the Genomics and Bioinformatics Core Facility, specializing in high-throughput sequencing data generation and analysis. Dr. Humphreys holds a Bachelor of Science (Honours, 1994) and Doctor of Philosophy in Biological Sciences (1999). His primary research focuses on bioinformatics, transcriptomics, microRNAs, and congenital heart disease, with expertise spanning genomics, gene expression analysis, and epigenetics. He maintains active collaborations with faculty at the Victor Chang Institute and cardiologists at St Vincent's Hospital, employing RNA-Seq and exome/genome sequencing techniques. Dr. Humphreys has received notable scientific awards including the 2019 ABACBS Professional Bioinformatician award, 2015 NHMRC reviewer recognition, and multiple best presentation awards. His recent publications demonstrate a strong focus on cardiac development, genetic disorders, computational biology, and novel methodologies in genomics. As manager of the Genomics Core Facility, he oversees laboratory operations for sequencing library preparation and provides bioinformatics support for diverse research projects. His work bridges molecular biology and computational analysis to advance understanding of cardiovascular diseases and developmental disorders.

Satyanarayana R. Pondugulaمشاهده پروفایل

استاد

• Drug Discovery
• Drug Metabolism
• Drug Interactions
• +۷ مورد دیگر

Dr. Satyanarayana R. Pondugula is a Professor of Veterinary Anatomy in the Department of Anatomy, Physiology and Pharmacology at Auburn University's College of Veterinary Medicine. He joined Auburn University in August 2011 after completing his DVM from the College of Veterinary Science in Tirupati, India, and his PhD from Kansas State University in Manhattan, Kansas, followed by postdoctoral training at St. Jude Children's Research Hospital in Memphis, Tennessee. Dr. Pondugula's research focuses on adverse drug interactions, anticancer drug resistance, and anticancer drug discovery. His laboratory investigates the mechanistic role of xenobiotic receptors, drug-metabolizing enzymes, drug-efflux pumps, and inflammatory signaling pathways that contribute to adverse drug interactions and anticancer drug resistance. His team also works on identifying novel small molecules and natural products for their potential to prevent adverse drug interactions, anticancer drug resistance, and adverse effects of chemotherapy. Analysis of Dr. Pondugula's recent publications reveals a strong emphasis on drug metabolism, particularly the pregnane X receptor (PXR) pathway, and its role in drug interactions and cancer treatment. His work spans multiple areas including veterinary oncology, chemotherapy-induced side effects, natural product pharmacology, and the neurological effects of drug interactions. Recent publications focus on cannabinoid interactions with cancer therapies, cardioprotective effects of natural products against chemotherapy-induced toxicity, and the impact of environmental chemicals on hormonal systems. Dr. Pondugula actively participates in teaching Veterinary Anatomy II to veterinary medicine and graduate students, as well as Endocrinology, Receptorology, Cancer Biology & Genetics, Cancer Pharmacology & Drug Discovery, and Pharmacology Research Methods courses. He also offers research-based Undergraduate Research, Honors Research, and Honors Thesis courses to undergraduate students. His collaborative research spans multiple institutions and involves numerous undergraduate and graduate students, as evidenced by publications in the Auburn University Journal of Undergraduate Scholarship. His work has significant implications for understanding drug interactions, improving cancer therapies, and developing safer treatment protocols for both human and veterinary medicine.

• Breast Cancer
• Endocrine Signaling
• Hormone-Dependent Cancers
• +۵ مورد دیگر

Cathrin Brisken is an Associate Professor in Life Sciences at EPFL, with a secondary appointment at the Institute of Cancer Research London. She leads the Brisken Lab (https://brisken-lab.epfl.ch), focusing on breast cancer mechanisms, endocrine signaling, and precision medicine. Her roles include serving as Dean of the EPFL Doctoral School and co-founding the International Cancer Prevention Institute. Education: MD and PhD in Biophysics from the University of Göttingen, followed by postdoctoral training at MIT/Whitehead Institute and Harvard Medical School. Research interests center on hormonal regulation of mammary development and cancer, with breakthroughs in understanding sensor cell roles of estrogen/progesterone receptors. Her lab pioneered clinically relevant patient-derived xenograft models and investigates tumor dormancy, endocrine disruptors, and therapeutic targets in lobular carcinoma. Advising: Supervised over 15 PhD students (listed in detail in full description). Active in international committees like AACR Women in Cancer Research Council. Labs/Teams: Brisken Lab at EPFL develops innovative 3D ex vivo models and uses cutting-edge techniques like deep learning for spatial tissue analysis. Collaborates on programs like UPTIDER post-mortem tissue donation for metastatic research.

Aurora Esquela Kerscherمشاهده پروفایل

دانشیار

• Cancer Biology
• MicroRNA Research
• Developmental Biology
• +۳ مورد دیگر

Aurora Esquela Kerscher is an Associate Professor of Cancer Biology in the Department of Microbiology and Molecular Cell Biology at Eastern Virginia Medical School (EVMS). She also holds an adjunct position as Adjunct Assistant Professor in the Department of Applied Science at the College of William & Mary. Her research focuses on understanding the role of microRNAs (miRNAs) in cancer progression and development, leveraging the nematode Caenorhabditis elegans as a model system to uncover conserved mechanisms. Dr. Kerscher's education includes a B.A. from Washington University in St. Louis, an M.S. and Ph.D. from Johns Hopkins University School of Medicine, and postdoctoral training at Yale University. Her work investigates how miRNAs like lin-4 and let-7 families regulate developmental processes and cancer-associated pathways, with a particular emphasis on their roles in urothelial cancers such as prostate cancer. She aims to identify miRNAs as diagnostic biomarkers and therapeutic targets. Her research integrates C. elegans genetics with mammalian cell culture and mouse models to study miRNA function in cancer. Key areas include miRNA-mediated gene regulation, tumor suppression, and oncogene activation. Despite no explicitly listed awards or grants in the text, her contributions to miRNA biology have been widely recognized in the field. Dr. Kerscher’s lab actively explores the translational potential of miRNA discoveries, focusing on bridging basic research with clinical applications in cancer therapy and diagnostics. She collaborates with institutions to advance understanding of miRNA pathways in both developmental and pathological contexts.

• Liver Regeneration
• Hepatic Stem Cells
• DNA Damage Response
• +۷ مورد دیگر

Sanjeev Gupta, M.B.,B.S., M.D., is a Professor in the Department of Medicine (Hepatology) and Department of Pathology at Albert Einstein College of Medicine. He holds the Eleazar & Feige Reicher Chair in Translational Medicine. His research focuses on liver regeneration mechanisms, hepatic stem cell biology, and DNA damage response pathways involving ATM, with applications in therapeutics and translational medicine. Gupta employs cell transplantation, animal models, and advanced molecular techniques to study liver diseases including acetaminophen toxicity, Wilson’s disease, and nonalcoholic fatty liver disease. Education & Training: Medical Degree from Sardar Patel Medical College, University of Rajasthan. Residencies at Jacobi Medical Center, Postgraduate Institute of Medical Education & Research, and Hammersmith Hospital. Fellowships at Hammersmith Hospital, Los Angeles County and University of Southern California, and Jacobi Medical Center. Research Interests: Investigates liver regeneration across development stages, studying cell type-specific contributions and stem cell roles. Explores DNA damage responses (ATM pathways), drug/toxin effects, and therapeutic strategies like cell/gene therapy. His lab uses decellularized biological scaffolds for liver tissue engineering and employs metabolomics for directed stem cell differentiation. Collaborates with multidisciplinary teams to advance translational therapies. Key Findings: Demonstrated paracrine signaling roles in hepatocyte transplantation, identified copper and arsenic toxicity mechanisms via ATM pathways, and developed models of Wilson’s disease and liver fibrosis. His work bridges basic science with clinical applications, using established drugs to interrogate mechanisms and guide therapies. Grants & Collaborations: Leads projects integrating microarray/sequencing with human tissue analyses. Collaborates with Einstein investigators and institutions globally. Focuses on translational tools like engineered liver constructs and drug repurposing. Labs/Teams: Engaged in tissue engineering and cell therapy research at Einstein’s Resnick Campus. Directs studies on hepatic microvasculature reconstitution and decellularized organ models.

Ikramuddin Aukhilمشاهده پروفایل

استاد

• Wound Healing
• Tissue Regeneration
• Extracellular Matrix Biology
• +۳ مورد دیگر

Dr. Ikramuddin Aukhil is the Associate Dean for Faculty Affairs and Professor in the Department of Surgical Sciences at East Carolina University's School of Dental Medicine. He holds a BDS from Bangalore University and an MS in Periodontology from the University of Michigan. His research focuses on wound healing, tissue regeneration, and molecular biology of inflammation. He has held academic leadership roles, including Chair of Periodontology at the University of Florida (2005–2022). Dr. Aukhil has been awarded multiple NIH grants (NIDCR) and has contributed to over 70 peer-reviewed publications. He maintains a part-time clinical practice in periodontology. His work spans genetic, epigenetic, and cellular mechanisms in periodontal diseases, with emphasis on African-American populations and translational research in regenerative therapies. Education: BDS, Bangalore University, India MS in Periodontology, University of Michigan, USA Research Interests: Combining molecular biology and clinical practice to address periodontal diseases, with special focus on wound healing pathways, extracellular matrix dynamics, and genetic factors influencing disease progression. Active in translational research bridging basic science and clinical applications. Grants & Awards: Continuous NIH RO1 Research Grants (1983–2019) Industrial Research Contracts NIH Study Sections Service Professional Activities: Leadership roles at UNC Chapel Hill and University of Florida, involvement in academic governance and faculty development. Active in American Dental Association, American Academy of Periodontology, and other scientific societies.

Thomas McFallمشاهده پروفایل

استادیار

• Cancer Biology
• Systems Pharmacology
• Genomic Medicine
• +۳ مورد دیگر

Thomas McFall, PhD, is an Assistant Professor in the Department of Biochemistry at the Medical College of Wisconsin. His research focuses on systems biology approaches to resolve clinical controversies in cancer therapy, particularly in RAS signaling, MAPK pathways, and progesterone receptor dynamics. He holds an MBA and has experience in strategic development for nonprofit and for-profit collaborations. Education: PhD in Oncology & Cancer Biology (Wayne State University), Postdoc at Salk Institute, MBA (Davenport University) Key research interests include synthetic lethality in cancer therapy, mechanisms underlying EGFR inhibitor sensitivity in KRAS-mutant cancers, and the interplay between estrogen and MAPK signaling in ovarian cancer. His work has been published in journals like Science Signaling and Cell Reports . Recent studies have identified biomarkers for therapeutic response in pancreatic and colorectal cancers, emphasizing precision medicine strategies. McFall’s findings on KRAS G13D mutant sensitivity to EGFR inhibitors have challenged clinical guidelines and advanced mechanistic understanding. Scientific Awards: None explicitly listed in the provided text. Advising and grants: No formal advisees listed, but leadership roles in drug discovery at Ideaya Biosciences and contributions to clinical trial data analysis highlight his collaborative research impact. Current projects integrate systems biology with oncology to improve treatment selection for exceptional responders. Labs/Teams: His research program combines systems pharmacology, MAPK signaling, and nuclear receptor studies, though specific lab names are not mentioned.